Renamed Coave Therapeutics Raises $39m To Fund Its Next-Gen Gene Therapies
Conjugation Tech Could Improve Gene Delivery
Executive Summary
The company aims to overcome drawbacks of existing gene therapy platforms, starting in ocular and CNS diseases.
You may also be interested in...
Deal Watch: Appili Gets AiPharma’s Help In Advancing COVID-19 Therapy
Appili brings in AiPharma to help with US/Canadian development of Fujifilm’s potential COVID-19 preventative/therapeutic. Other recent tie-ups include CinFina/Janssen, Bone/Impant, Bayer/Gubra, Novartis/Theragnostics, Grifols/Biotest and more.
GenSight CEO Sees Bright Future After Therapy Gave Blind Man Partial Sight
French biotech GenSight will prioritize its optogenetic GS030 treatment after the combination showed breakthrough results in a form of blindness, its CEO tells Scrip.
Omicron Clouds Novavax’s Delayed COVID-19 Vaccine Debut
Novavax has already gained its first emergency use authorization for its COVID-19 vaccine, but doubts remain about its manufacturing and Omicron readiness.